Panacea Biotec receives licence to produce Sputnik V vaccine at Himachal Pradesh by admin- Monday, July 5th, 2021 04:02:54 PM
Panacea Biotec introduced receipt of producing license from Drugs Controller General (India) for Sputnik V vaccine in opposition to Covid-19 pursuant to its collaboration with Russian Direct Investment Fund (Russia’s sovereign wealth fund). The license is a vital condition for the usage of Sputnik V produced by way of Panacea Biotec in India.
The batches produced at Panacea Biotec’s centers at Baddi, Himachal Pradesh have been in advance shipped to the Gamaleya Center in Russia for excellent manipulate. The stated batches have successfully passed all the exams for high-quality parameters both on the Gamaleya Center in Russia and on the Central Drug Laboratory, Kasauli, Himachal Pradesh in India.
Sputnik V was registered in India underneath the emergency use authorization method on April 12, 2021 and vaccination in opposition to Covid-19 with the Russian vaccine started on May 14, 2021.
Sputnik V has been registered in 67 countries globally with overall populace of over 3.5 billion human beings.
The vaccine is based totally on a tested and properly-studied platform of human adenoviral vectors and makes use of two one of a kind vectors for the 2 pictures in a path of vaccination, offering immunity with an extended length than vaccines using the equal delivery mechanism for both pictures.